We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Link to IBS Identified in Women

By LabMedica International staff writers
Posted on 18 Apr 2018
Irritable bowel syndrome is the most common gastrointestinal disorder. More...
More than 10% of the population suffers from recurrent symptoms including abdominal pain, gas, diarrhea and constipation and it is more common in women than men.

A new study links certain DNA variants to increased risk of irritable bowel syndrome (IBS) in women. The findings might help explain why IBS is more common in women than in men. The study has identified DNA variants that are associated with increased risk of IBS, but only in women.

A large team of international scientists led by the Karolinska Institutet (Stockholm, Sweden) performed a genome-wide association study (GWAS) of the large UK Biobank population-based cohort, which includes genotype and health data from 500,000 participants. By following up this result in 2,045 patients from IBS expert centers in Sweden, Belgium, the Netherlands, Italy and the USA, the investigators observed further associations with constipation-predominant IBS as well as harder stools, again only in women.

The scientists identified a genome-wide significant association on chromosome 9q31.2 (SNP rs10512344), in a region previously linked to age at menarche, and 13 additional loci of suggestive significance. Sex-stratified analyses revealed that the variants at 9q32.1 affect risk of IBS in only women and also associate with constipation-predominant IBS in women and harder stools in women in the population-based sample. Functional annotation of the 9q32.1 locus identified eight candidate genes, including the elongator complex protein 1 gene (ELP1 or IKBKAP), which is mutated in patients with familial dysautonomia.

Mauro D'Amato, PhD, an Associate Professor of Molecular Genetics and senior author of the study, said, “Exploiting the large UK Biobank resource, as well as several patient cohorts from European and USA expert centers, we have been able to study genetic predisposition to IBS with increased statistical power, better than ever before. Although we cannot point to individual genes at this early stage, we believe these results are exciting, as they converge with existing data on female preponderance and a role of sex-hormones in IBS.” The study was published on April 4, 2018, in the journal Gastroenterology.

Related Links:
Karolinska Institutet


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.